|
Oct 2
|
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
|
|
Oct 1
|
Dr. Reddy’s Acquires Global NRT Leader Nicotinell
|
|
Sep 28
|
Dr. Reddy’s Expands Portfolio with $620M Investment
|
|
Jul 29
|
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
|
|
Jul 29
|
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
|
|
Jul 27
|
Dr. Reddy’s Q1FY25 Financial Results
|
|
Jun 26
|
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
|
|
Jun 3
|
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
|
|
May 28
|
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
|
|
May 8
|
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript
|
|
May 8
|
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
|
|
May 7
|
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
|
|
May 3
|
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
|
|
Mar 22
|
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
|
|
Mar 19
|
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
|
|
Feb 5
|
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
|
|
Feb 2
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Feb 1
|
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
|
|
Feb 1
|
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
|
|
Jan 31
|
Dr. Reddy’s Q3 & 9M FY24 Financial Results
|